Abstract Introduction
Introduction
Autism Spectrum Disorder (ASD) is a lifelong developmental disorder characterized by challenges in social communication and the presence of repetitive behaviors and/or restricted interests. Many people with ASD experience symptoms of inattention and hyperactivity, and approximately one-third of people with ASD are diagnosable with attention deficit hyperactivity disorder (ADHD) (1, 2). There are considerable gaps in knowledge in how to provide optimal assessment and management of this group of patients (3). Early diagnosis and intervention are beneficial for both ASD (4) and ADHD (5). Evidence from genetic, cognitive, and behavioral research suggests that when ADHD and ASD co-occur, they may be considered a separate overarching condition (6) (7) (8) , and a variety of ASD-ADHD developmental subtypes have already been proposed (9).
The combination of ASD and ADHD has been linked to both greater cognitive impairment (10, 11), general psychopathology (12, 13), emotional processing impairment (14) , and significantly higher rates of some hyperactivity/impulsivity symptoms compared to individuals with ADHD alone (15). Furthermore, the co-occurrence of ADHD and ASD is associated with a greater risk of developing other psychiatric disorders such as schizophrenia, bipolar disorder, and anxiety disorder, compared to controls and individuals with either condition alone (16). The pervasive nature of impairments in social communication and attention across psychiatric disorders may suggest that these deficits should be investigated transdiagnostically, an approach advocated by the NIMH Research domain criteria RDoC framework (17). Attentional and social communication deficits have been identified in many disorders of brain function including schizophrenia (18, 19) , bipolar disorder (20, 21), anxiety disorders (22), and traumatic brain injury (23, 24) . Therefore, the study of individuals with combined ASD and ADHD can help elucidate the basis of a wide variety of disorders of the brain.
It is there important to address ADHD, and while the leading approach has been psychopharmacological medication, people with co-occurring ASD and ADHD have been found to be less likely to receive appropriate treatment for their ADHD (15) , and appear to respond less favorably to treatment when compared to individuals with ADHD alone (25) . Additional concerns about ADHD treatment, in particular stimulant medication, focus on their longterm effectiveness (26), side effects (27), and parental reservation about their use (28) . Yet, evidence also shows that leaving individuals with untreated ADHD may lead to considerable negative social and behavioral sequelae, including greater risk of academic failure (29), alcohol and drug use (30), and contact with the criminal justice system.
There has been growing interest in the use of cognitive training in ADHD, a non-pharmacologic approach that may utilize neurofeedback and/or novel digital approaches. Recent studies have shown promise (31, 32) although historic interventions have raised questions regarding their effectiveness (33). There is also concern that technology may actually prove to be distracting, and reduce learners' attentiveness to educational tasks (34-36).
Little research has described the impact of digital interventions on people with ASD who demonstrate ADHD symptoms (37). There has been some preliminary research to show the utility of augmented reality interventions in ASD samples (38) (39) (40) . Intervention based on augmented reality has also been shown to help to improve ADHD symptoms in people with ASD, with improvements in both selective and sustained attention in children with ASD (38). We have previously described the delivery of social communication coaching on augmented reality smartglasses via Empowered Brain (previously the Brain Power Autism System; (41). Our early pilot report on two boys with ASD demonstrated short-term improvements in the hyperactivity subscale of the Aberrant Behavioral Checklist (ABC-H) (41), a validated instrument that assesses hyperactivity, impulsivity, attention, and non-compliance (42). The ABC-H has previously been used as a key outcome measure in ADHD treatment studies in children with .
In this study, we explore the short-term effect of an Empowered Brain intervention on ADHD symptoms in a group of 8 children and adults with ASD. We document caregiver-reported ADHD symptoms as measured by the ABC-H and discuss the implications of these results on future research in the field.
The Empowered Brain system
Empowered Brain is a combination of modern smartglasses and educational modules targeting socio-emotional and behavioral management skills (41, 48) . Smartglasses are lightweight head-worn computers with a small transparent display that can provide guidance to users through both visu audio cues (Figure 1 ). Empowered Brain can c wide variety of user data through an in-built array that includes camera, microphone, touc "blink" sensor, gyroscope, and acceler Empowered Brain includes modules that utiliz sensors to deliver social communicatio cognitive skills coaching. This digital approa be particularly valuable to both people wit (49) and people with ADHD (50, 51). Figure 1 . Google Glass, prototypical head-worn smartglasses with in-built sensors, as well as a small scr and a bone conduction speaker to provide a private audio-visual experience. Empowered Brain integrates Google Glass with a range of assistive and educational modules. Modules were developed through an iter user-centered design and evaluation process in conjunction with behavioral specialists and families with a children.
For example, Empowered Brain incorporates the Face2Face module, software that helps guide users to pay attention to socially salient visual stimuli (human faces; Figure 2 and Figure 3) . The ability to pay attention to important social stimuli, and to direct gaze towards the most socially salient features of the face, have been identified as a key challenge in ASD (52). When the Face2Face module is running, Empowered Brain is able to identify the pres human faces within its visual field, and help users towards the human faces through en visual cartoon-like images and guidance arro the user pays more visual attention to the huma they earn points and other in-game reward points stop accumulating after a short period to avoid coaching users to stare. Additionally, the system incorporates mechanisms to alter the difficulty associated with using each gamified app. One method is to alter the attentional challenge by displaying virtual elements that will either help to enhance attention, or to act as distractors to the social stimuli that the user is tasked to interact with. These virtual elements are overlaid over the user's real-world view and include both dynamic real-time positional cues based on user movement and physiology, as well as reward-based virtual elements that provide feedback on the user's in-app performance.
A series of research studies have investigated the use of Empowered Brain in ASD samples. 
Methods

IRB Approval
The methods and procedures of this study were approved by Asentral, Inc., Institutional Review Board, an affiliate of the Commonwealth of Massachusetts Department of Public Health.
Participants
Eight children and adults with ASD signed up to take part in this research through a web-based research interest form (average age: 15 years, range 11.7 -20.5; 7 males, 1 female). Participant demographics are summarized in Tables 1 and 2 . Written consent was obtained from the legal guardians of children and from cognitively-abled adults. Participants between 7
and 17 years-old provided written assent, when they were able to.
All caregivers of participants were questioned whether they had a past history of ADHD, and whether they were currently receiving treatment for ADHD. Additionally all participants had a baseline ABC-H and Social Communication Questionnaire (SCQ) (57).
Method
The ABC-H is a subscale of the ABC, and measures key ADHD symptoms such as inattention, impulsivity, and hyperactivity. The ABC has been extensively used in the developmentally disabled population, and the ABC-H has been used as an outcome measure of studies that have investigated the treatment of ADHD in populations with concurrent ASD (43-47). In the assessment of ADHD symptoms in ASD, the ABC has shown itself to have superior psychometric properties, in particular validity (58) and reliability (59), compared to other rating scales of ADHD symptoms in children with developmental disorders (such as ASD). The ABC-H includes items that rate key ADHD symptoms. Specifically, the ABC-H assesses inattention/impulsivity through items that require the rater to assess whether client is "easily distractible", "does not pay attention to instructions", "pays no attention when spoken to", or is "impulsive".
Following these baseline assessments, the participants were stratified into high and low ADHD symptom groups based on their baseline ABC-H score. The cut-off scores for the high ADHD group is13 for male participants, and 8 for the single female participant. These scores were determined by prior research that recorded the ABC scores for a sample of 666 people with developmental disorders, and found a mean ABC-H score of 13.38 for males and 8.12 for females (60).
Accordingly, males with a score of 13 or higher and females with a score of 8 or higher were considered to have high ADHD symptoms (mean high ABC-H group score = 25.75), while those with a lower score were deemed as having low ADHD symptoms (mean low ABC-H group score = 5.5). Half of the participants had a history of ADHD (n = 4, 50%), three of whom were receiving active treatment at the time of testing. Of note, based on their ABC-H scores as above, two participants that were previously diagnosed with ADHD were categorized in the low ADHD symptom group, while the remaining two were categorized into the high ADHD symptom group. Despite the past history of ADHD diagnosis, the ABC-H was used as a stratification method as it provided a numerical measure of recent (baseline) ADHD symptom burden. This numerical subscale allows for a more quantitative measure of change in rated items. While a clinical history of ADHD was obtained for the participants, the clinical diagnosis of ADHD in ASD is challenging (61), and it was only with the release of the DSM-5 (62) that it became possible to diagnose ADHD in an individual with ASD. Prior to the release of the DSM-5, the DSM-IV TR specifically excluded a diagnosis of ADHD being made when an individual had a diagnosis of ASD. Therefore, while background information regarding ADHD history is important, the ABC-H was felt to be a more accurate measure of ADHD symptom load to determine the stratification into low and high ADHD symptom groups.
All participants had a baseline SCQ (57) as a validated measure of their ASD symptoms. The SCQ score demonstrated that participants represented a wide range of social communication abilities, from 11 to 28 points (mean score 18).
Procedure for Testing
All participants were accompanied by a caregiver to the testing session. The participants and their caregivers were oriented to Empowered Brain and Google Glass, and their ability to tolerate wearing the smartglasses was measured. Once the participants showed they were able to wear the smartglasses for at least one minute, the participants were able to use Empowered Brain social communication modules and had a series of gamified experiences while interacting with their caregiver, including using Empowered Brain modules such as Face2Face and Emotion Charades (Fig. 2, 3 ). Empowered Brain modules help users to recognize and direct their attention towards socially salient stimuli such as human faces (in particular, the central part of the face, including eye regions), emotional facial expressions, and changes in social environment. Participants and caregivers were able to verbalize any concerns or difficulties in using Empowered Brain both during and immediately after the session. An ABC-H score was obtained at 24-hours and at 48-hours post session through the caregiver's report. A clinically significant change in ABC-H was determined by a 25% or more change in the score, a standard that has previously been utilized in combination with another scale to determine responders to ADHD treatment in an ASD population (43). 
Exclusions Individuals who had expressed interest via the website signup but who had a known history of epilepsy or seizure disorder were not enrolled in this study. Users who had any uncontrolled or severe medical or mental health condition that would make participation in the study predictably hazardous were also not eligible for enrollment. Information regarding potential exclusions to this study was obtained directly from the caregivers of the participants.
Results
All participants were able to use smartglasses and complete the coaching session. The high ADHDrelated symptom group had a similar ASD severity to the low ADHD-related symptom group (18.5 vs 17.6 SCQ score), but consistent of younger participants (12.5 vs 17.6 years). ABC-H scores were lower postintervention for most participants at 24 hours (n = 6, 75%), and for all participants at 48 hours (n = 8, 100%). At 24-hours post-session, average ABC-H scores decreased by 54.4% in the high ADHD symptom group and by 20% in the low ADHD symptom group. At 48-hours post-session ABC-H scores compared to baseline decreased by 56.4% in the high ADHD symptom group and by 66.3% in the low ADHD symptom group.
The high ADHD-related symptom group consisted of four participants who demonstrated an average ABC-H score of 25.75 at the start of the study (Table 3) . The high ADHD-related symptom group reported a reduction in average ABC-H score at 24-hours (ABC-H score: -12, -54.9% reduction from baseline) and at 48-hours post-session (-11.75, -56.4%). The low ADHD-related symptom group consisted of four participants who had an average ABC-H score of 5.5 at the start of the study (Table 4) . The low ADHDrelated symptom group had decreased average ABC-H score at 24-hours (-1, -20%) and 48-hours postsession (-3.5, 66.3%). The average reduction in ABC-H score for the high ADHD-related symptom group was greater than the low ADHD-related symptom group at both 24-hours (12 vs 1 point) and 48-hours (11.75 vs 3.5 points) post-session. The ABC-H scores of the participants are presented graphically in Figure  2 .
It is noted that while the participants in the high ADHD-related symptoms group were younger, they had a similar ASD symptom severity as measured by the SCQ to the low ADHD-related symptom group. It is perhaps not a surprise to find that the high symptom group was younger given that the ABC-H subscale is weighted towards hyperactivity, and hyperactivity is an ADHD-symptom that improves with age (63). 
Discussion
While many people with ASD struggle with symptoms of ADHD, including hyperactivity, impulsivity, and inattention, considerable gaps in knowledge remain in regard to their optimum assessment and management (3). The combination of ADHD and ASD has not only been linked to greater impairment (10, 11) and psychopathology (12, 13), but also reduced access and response to psychopharmacological treatment for ADHD (15) (25). These are important considerations given the substantial negative sequelae of untreated ADHD (29, 30). There has been increasing interest in developing digital interventions to address the symptoms of ASD or ADHD, but few technological interventions have been studied for people with ASD and ADHD symptoms. This population may potentially benefit from such approaches.
All participants managed to complete the Empowered Brain intervention session without any reported negative effects, and all participants tolerated using smartglasses for the duration of the testing session. This is important as a major limiting factor in the use and continued engagement of assistive technologies is their usability, tolerability, and associated negative effects.
Most participants demonstrated improvements in ADHD-related symptoms following the intervention at both 24 hours (n = 6, 75%), and 48 hours (n = 8, 100%) post-session. One participant in the high symptom group was noted to have had a greater reduction at 24 hours than 48 hours, while a participant in the low symptom group was noted to have had an increase in ADHD-related symptoms at 24 hours followed by a large decrease from baseline at 48 hours.
When group mean ABC-H changes are calculated, the high ADHD-related symptom group demonstrated a significant response (greater than 25% improvement in ABC-H score) at both 24-and 48-hours (-54.9% and -56.4%, respectively). The low ADHD-related symptom group appears to have demonstrated a response at 48-hours (-66.3%), but not at 24-hours (-20%). The authors, who include subspecialist clinicians, advise caution in assessing the low ADHD-related symptom group, given the low baseline and small absolute score changes. Such results may render the findings in this group as not being as clinically significant as the outcomes associated with the high ADHD-related symptom group. Future larger studies would allow for more robust statistical analysis and conclusions to be made.
There are several important limitations to this work that deserve mention. Firstly, the number of children and adults in this report was relatively small (n = 8), although a sizeable sample relative to other research on novel technologies in ASD, especially in regard to other smartglasses research (41, 48) . While quantitative approaches using validated scales are very useful, future research efforts would also benefit from the use of qualitative approaches, and some early results of such methods have been reported (55).
We should certainly consider the potential for a expectancy effect (64) in using this technology, especially given that the testing session was a novel experience for both the participant and the caregiver. However, the potential for this effect should also be tempered by our knowledge that transitions or new experiences have been associated with extreme distress in people with ASD, so much so that it is a characteristic part of diagnosis (62). We noted that none of the participants encountered any noticeable distress or problems with using the smartglasses.
It would be useful for future research to incorporate a larger sample size, with more female participants. One can also see the benefit of age-matched neurotypical and ADHD-only controls. While the ABC-H is a very useful scale to use in this context, the use of broader ADHD-related measures would also provide for further insights. Despite our findings, the broader generalizability of our results to the wider ASD population will remain limited until further research is undertaken.
This report can hopefully pave the way for more funding and interest to study the potential application of this emerging technology to not just dually diagnosed ADHD and ASD samples, but more broadly to other categorical psychiatric diagnoses that also exhibit both attentional and social communication impairments. Such diagnoses include schizophrenia, bipolar disorder, and anxiety disorder. While deficits in social communication occur across many psychiatric disorders, the major of digital social communication interventions have been studied in ASD alone (65). Therefore, research and development of an intervention that can target transdiagnostic symptoms could be valuable in both clinical scenarios, and in research utilizing the RDoC framework.
Smartglasses may have a particularly unique role in this respect, as they also contain a variety of quantitative sensors that are more closely located to the main perceptual apparatus of the brain than any other wearable technology. These sensors can collect and help analyze sensor data to help classify human behavior. This digital phenotyping approach aims to detect changes in affective and behavioral states associated with both improvements and deteriorations in psychiatric disorders, and help to identify new methods to subtype disorders (66).
Conclusion
Empowered Brain is a smartglasses-based social communication intervention that has been previously shown to improve social communication functioning in ASD. This report provides early evidence for the efficacy of Empowered Brain to reduce ADHD symptoms, such as hyperactivity, inattention, and impulsivity, in school-aged children and adolescents with ASD. Our results also suggest that, despite concerns about increased distraction and reduced attentiveness, the intervention did not result in any increased ADHD symptoms in any of the participants at 48 hours post-intervention. Empowered Brain is being developed as a tool that can be used by caregivers, therapists, and educators to deliver socio-emotional interventions to users with ASD. It is designed as a tool that can be used on a daily basis for 10-20 minutes per intervention. While this study reports on the impact of Empowered Brain on ADHD symptoms after a single intervention, further research is required to understand how the longitudinal use of this technology may impact ADHD symptoms in people with ASD. This technology also has potential to address the attentional and social communication deficits that are transdiagnostically present across psychiatric disorders. Data collection via sensors that are proximally situated to the principal human perceptual organs may result in a more ecologically valid digital phenotyping approach. This digital phenotyping approach may aid the research of proposed developmental subtypes of a distinct ASD-ADHD combination disorder, and more broadly, psychiatric and brain injury-related disorders. 
